Which of the two stocks would you prefer?
GlaxoSmithklineGB00BN7SWP63GSKGSK
Hello Community,
I'm reporting here because I can't get rid of a topic. It is now somehow not so dramatic, but since I like to have things neat (especially statistics ;)) I think about it again and again.
First of all: I have my account with ING. There I have at the time of the demerger/reverssplit of $GSK (old) held. These were then as expected by $HLN (-2.35%) shares in the same amount and then the GSK shares were exchanged for new $GSK (-2.62%) shares in a ratio of 5:4.
So far so good. But now GSK has taken the purchase value of the old GSK shares and simply split it 50/50. That means on the new GSK shares I have a nonsensically low purchase value (and am accordingly strongly in the plus) and with those of Haleon I have a nonsensically high purchase value, clearly over what was ever possible with the share.
Of course, it's great that if Haleon develops positively, I don't have to pay taxes on this increase in value when I sell it. However, if I sell GSK, I will be asked to pay a lot of money because it is almost 60% up. Does not feel right.
To make it perfect this did not happen analogously at Getquin.... But that could also be due to the fact that the ING to top it all off has also first settled Anders, then canceled and then divided as discussed...
Now the question, how were the acquisition values divided with you?
After the spin-off and the spin-off of the Consumer Health division, my investment case in GSK no longer fits.
Financials
Market Cap
$86.68B5Y beta
0.57EPS (TTM)
$1.301Free Float
4.08BP/E ratio (TTM)
16.07Revenue (TTM)
$41.76BEBITDA (TTM)
$14.00BFree Cashflow (TTM)
$3.77BPricing
Analyst Ratings
The price target is $25.79 and the stock is covered by 24 analysts.
Buy
12
Hold
10
Sell
2
Information
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.